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tricht University, and Olga Melnikova, REC 
PAST-Centre, Tomsk State National Re-
search University
Crossing boundaries is a challenge of our time. 
Representatives from a diverse range of disci-
plines and fields came together at the conference 
“Social Sciences and Medical Innovations”1 in 
order to discuss the dynamics of innovation in 
biomedicine and public health, as well as rela-
tions between such innovations and society. The 
conference was jointly organised by the Centre 
for Policy Analysis and Studies of Technologies 
(Tomsk State University, Russian Federation) 
and the Department of Health, Ethics and Soci-
ety (Maastricht University, The Netherlands). In 
view of the fact that social sciences play a crucial 
role in understanding the processes and challeng-
es of medical innovations, participants discussed 
the opportunities created by engagement between 
social and biomedical scientists, health profes-
sionals and policy makers. This highly interdis-
ciplinary event brought together participants pre-
dominantly based in European and post-Soviet 
states, establishing novel connections between 
scholars involved in the field of medical inno-
vations and engaged with different traditions of 
thought and disciplinary languages. Correspond-
ingly, the questions raised in the course of the 
conference were diverse: How innovations in 
medicine and health are actually developed and 
how the relationships between innovations and 
everyday practices are mediated? What concepts 
and theoretical approaches are fruitful for under-
standing innovative initiatives in biomedicine 
and their meanings and consequences for the 
various actors involved? What concepts and ap-
proaches are useful for envisioning and reflect-
ing on the future directions of innovations? How 
are medical innovation agendas shaped and what 
kind of governance processes are and should be 
involved? How do rapid scientific advances and 
new technologies address issues of public partic-
ipation and accountability?
1 Innovation Governance
The conference was opened with an introductory 
keynote lecture by Klasien Horstman (Maastricht 
University). She provided a narrative of how the 
social has been gradually divorced from biomed-
ical knowledge production and innovation in 
the course of the scientification of medicine and 
showed the costs of such separation. Moreover, 
she pointed to the difficulties in bridging the gap 
between laboratories and medical practice and in 
understanding the effectiveness of innovations 
in everyday life, the lack of attention to what it 
means to live with biomedical innovations, and 
the limited insights into issues of public legitima-
tion of expertise. She called for more interaction 
and dialogue between social sciences and medi-
cal innovations in order to reflect on socio-tech-
nical trajectories and to continuously learn about 
their quality, consequences and anticipations.
Agnes Meershoek (Maastricht Universi-
ty) began the session “Innovation Governance” 
by reflecting on the limitations of the view that 
development and implementation of (medical) 
innovations are two separate phases of a knowl-
edge-driven process. Noting that it is nearly im-
possible to control the implementation and use 
of new technologies, the pervasive influence of 
societal dynamics on knowledge production, and 
the decreasing public trust in science, she stressed 
the need to democratise innovation governance. 
Further, Valentina Poliakova (National Research 
University Higher School of Economics, Mos-
cow) talked about the ambiguities and conflicts 
surrounding new biomedical technologies, e.g. 
the boundaries between human and non-human 
and the divergence between health and social 
risks, and examined the example of social legiti-
mation of stem cell technologies in Russia. Pavel 
Vasilyev (Max Planck Institute for Human De-
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velopment, Berlin) delved into the early history 
of Soviet health care and investigated the evolu-
tion of government policy towards private health 
services provision. Olga Zvonareva and Lloyd 
Akrong (Maastricht University) discussed the 
development of regulations for governing bio-
medical knowledge production and showed how 
globalised research ethics guidelines and bioeth-
ical discourses are being re-interpreted and op-
erationalised in particular local settings, arguing 
for more responsive and empirically informed 
governance tools.
2 Co-production of Science and Society
In the second keynote lecture, Jessica Mesman 
(Maastricht University) talked about the “in-
terventionist turn” in Science and Technology 
Studies (STS) and her own efforts to make a 
difference in clinical practices related to patient 
safety. Elaborating on the issue, she focused on 
the positive understandings of patient safety, on 
latent resources and strengths allowing for ad-
equate levels of safety within complex real-life 
situations, which can be considered as exnova-
tion. She stressed that qualitative, anthropolog-
ical research is an important means of interven-
tion and provided video reflexivity as an example 
of a method extensively applied in her own work.
The subsequent conference session “Co-pro-
duction of Science and Society” explored the 
processes and multiple perspectives involved in 
the generation of new health-related knowledge. 
The issue of credibility was brought in by Bart 
Penders and Melanie Leenen (Maastricht Uni-
versity), who analysed how the credibility of al-
ternative dietary advice, i.e. the food hourglass, 
was engineered by its author through combin-
ing a critique of the dominant scientific para-
digm with selective enlisting of that paradigm. 
The topic of credibility was also taken up by 
Evgeny Kulikov (Academy of Evidence-Based 
Medicine, Russia), who discussed the struggles 
surrounding the introduction of the influential 
paradigm of evidence-based medicine in Rus-
sian settings. Denis Sivkov (Russian Presidential 
Academy of National Economy and Public Ad-
ministration) reflected on divergent ontologies of 
the immune system. The idea of multiplicity of 
ontologies and its implications was further elab-
orated on by Victor Vakhshtayn (Moscow School 
of Social and Economic Sciences), exploring (re)
conceptualisations of trauma. Further, Maria Po-
likashina (National Research University Higher 
School of Economics, Moscow) discussed med-
ical and social notions of the human body, and 
Andrey Kuznetsov (National Research Tomsk 
State University; Volgograd State University), in 
his presentation, suggested that the clinic could 
be a strategic site to look for “the social”.
3 Gender and Cultures in Medical 
Innovations
The session on “Innovations, Medicine and Gen-
der” was opened by Anna Temkina (European 
University at St. Petersburg), who focused on the 
issues of access to newly reformed, highly tech-
nological care for pregnant women and women 
giving birth in Russia. She described various 
ways of accessing healthcare and developing 
trust between patients and medical professionals 
and, importantly, showed how the idea of “ac-
cess” in practice was not at all straightforward; 
rather it is organised through continuous nego-
tiations in the context of multiple uncertainties. 
Ekaterina Borozdina (European University at St. 
Petersburg) explored how the midwifery com-
munity in Russia was working to redefine birth 
assistance practices and institutionalise these 
innovations, taking account of the influences of 
Soviet experiences, current liberal reforms in 
the healthcare system, and the interventions of 
global actors. Using the example of anesthesia 
application, Olga Melnikova (National Research 
Tomsk State University) focused the audience’s 
attention on how technologies in medical practic-
es were used in multiple and creative ways, not 
limited to those specified by medical standards. 
Valentina Shipovskaya (University of Zurich) 
talked about gender differences in healthy aging 
and ways to measure them; Daria Schechvatova 
and Olga Kurushina (Volgograd State Medical 
University) focused on the role of gender and 
corresponding perceptions and expectations in 
doctor-patient relationships; and Polina Vlasen-
ko (Centre for Society Research, Ukraine) criti-
cally analysed the discourses of the state, medi-
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cal professionals, and patients regarding assisted 
reproductive technologies (ART) and discussed 
biopolitical and governmentality techniques for 
gender normalisation in Ukraine.
During the session “Cultures in Medicine”, 
Nina Bagdasarova (American University of Cen-
tral Asia, Kyrgyzstan) and Karen Petrosyan (Uni-
versity of Massachusetts) explained that the use 
of “soft” innovations like diagnostic manuals in 
medicine was embedded in societal perceptions 
and conditions, and gave an example of defin-
ing depression in post-soviet Kyrgyzstan. Anna 
Leontyeva (National Research University, High-
er School of Economics, Moscow) described 
the strategies used by people from stigmatised 
groups, including injection drug users, to access 
medical and social services, stressing the impor-
tance of contextual socio-political circumstances 
in shaping these strategies. Svetlana Abrosimova 
(Ural Federal University) talked about how ad-
vances in medicine and biotechnology were in-
terpreted by various religious groups and the im-
plications this held for biomedical innovations.
4 Innovation Design and Implementation
Elena Simakova (University of Exeter) opened 
the concluding conference session “Innovation 
Design and Implementation” with a talk on re-
sponsible research and innovation, scrutinising 
the notion of responsibility itself and arguing in 
favour of opening up the relationships between 
technologies and responsibility for public delib-
eration. She drew attention to the need to further 
develop the field of the sociology of expectations 
in order to critically analyse promises and vi-
sions of (biomedical) innovations and avoid tak-
ing these for granted. Angelos Balatsas-Lekkas 
(Technical University of Denmark) discussed 
how medical professionals, engineers, psychol-
ogists, and others worked together in designing 
medical simulation sessions and negotiated their 
understandings of patient safety, focusing on 
transformative aspects embedded in the design 
of simulation scenarios and their implications 
for medical practices. Ivan Tchalakov (Nation-
al Research Tomsk State University; University 
of Plovdiv) suggested experimenting with the 
limits of participants’ imagination and reflected 
on health needs and productive solutions for the 
forthcoming human colonisation of space. Tetia-
na Stepurko (National University of Kyiv-Mohy-
la Academy) and other colleagues from the Na-
tional University of Kyiv-Mohyla Academy and 
Maastricht University investigated practices of 
informal patient payments in Lithuania, Poland 
and Ukraine, their relation to specificities of the 
economic and sociocultural environments, and 
their implications for future healthcare reforms. 
The session was closed with a presentation by a 
team from Perm National Research Polytechnic 
University headed by Elena Seredkina, who re-
ported on practices and challenges of designing 
and implementing a transdisciplinary project in 
the field of metabolism and diabetes.
5 Crossing Boundaries: Opportunities 
and Challenges for Collaboration and 
Dialogue
The issue of engagement of social scientists 
with biomedical scientists, entrepreneurs, poli-
cy makers, and other actors involved in health 
and medical innovations, and the value and risks 
associated with such engagement became one 
of the main axes of the conference. During the 
“Biomedical Innovations in Contemporary Rus-
sia and the World” round table, which brought 
together representatives from the Technolo-
gy Platform “Medicine of the Future”2, Tomsk 
Oblast Center for Cluster Development3, indus-
try and academia, it was reiterated that the in-
volvement of social sciences was crucial for at-
tuning innovations to the needs and concerns of 
diverse members of society in various contexts. 
In the final conference discussion, it was ac-
knowledged that relevant and responsible medi-
cal innovations require input and direct involve-
ment of many. Participants reflected on how to 
organise this multitude of voices, with all its 
asymmetries of power, diverse disciplinary cul-
tures and governance traditions, and discussed 
possible roles for social scientists, including that 
of the analyst, advocate, assistant, critic, referee, 
and commentator. It was shown that there are 
multiple reasons for social scientists to actively 
and purposefully “intervene” in medical innova-
tions and various ways to do so.
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Wann ist genug genug? Wie 
Wissenschaftler, Regulatoren 
und Innovatoren mit 
Wissenslücken umgehen
Bericht über den Workshop 
„Wissenschaftliche Grundlagen zur 
Regulation von Nanomaterialien“
Dübendorf, Schweiz, 20.–21. Januar 2014
von Jutta Jahnel, ITAS
Mittlerweile sind Nanoprodukte in jedem Su-
permarkt zu finden. Sie werden z. B. in Sonnen-
cremes, Reinigungsmitteln und Wundpflastern 
eingesetzt. Gleichzeitig besteht aber noch kein 
Konsens über die Bewertung der zahlreichen to-
xikologischen Studien, die mit immer aufwändi-
geren Methoden die Risiken von Nanopartikeln 
untersuchen. Analysemethoden zur Überwachung 
und Kontrolle von Kennzeichnungsvorschriften 
stehen zwar prinzipiell zur Verfügung, die Verfah-
ren sind jedoch sehr aufwändig, die Instrumente 
sehr teuer und die Messmethoden nicht validiert. 
In dieser Situation stellt sich die Frage nach dem 
verantwortungsvollen Umgang mit derartigen 
Unsicherheiten, nach dem möglichen Risiko für 
Verbraucher, aber auch nach den Voraussetzungen 
für Innovationsfreundlichkeit und Vertrauen in die 
Nutzung derartiger Technologien.
Der Workshop brachte insgesamt 30 Sta-
keholder aus Wissenschaft, Industrie, Behörden 
und Beratung – größtenteils aus den Bereichen 
Umwelt, Chemikalienbewertung, Analytik und 
Wasserversorgung – für zwei spannende Tage an 
einen Tisch. Er wurde vom Oekotoxzentrum der 
Eawag in Dübendorf organisiert. Die Teilnehmer 
hörten informationsreiche Vorträge, um einen 
gemeinsamen Wissensstand über aktuelle recht-
liche Regelungen aufzubauen. Danach wurden 
wissenschaftliche Grundlagen aus der Human-, 
Ökotoxikologie und der Analytik vertieft und 
offene Fragen thematisiert. Die aktive Mitarbeit 
der Teilnehmer erfolgte in kleineren Diskussi-
onsgruppen und konzentrierte sich auf gemein-
same Strategien für einen verantwortlichen Um-
gang mit Nanomaterialien.
1 Regulatorische Standortbestimmung
Andrej Kobe von der Europäischen Kommissi-
on gab einen Überblick über die regulatorische 
Situation von Nanomaterialien in der EU. In den 
letzten Jahren wurden auf europäischer Ebene 
zahlreiche Anpassungen in Sektor spezifischen 
Verordnungen für verbrauchernahe Nanoprodukte 
wie Kosmetika oder Lebensmittel zu Definitionen 
und Kennzeichnungen vorgenommen. Aber auch 
an Nanomaterialien, die als Rohstoffe in Nano-
produkten eingesetzt werden, wurden zusätzliche 
Vorgaben an die Hersteller bezüglich der Regist-
rierung und Informationsweitergabe festgelegt.
Christoph Studer (Bundesamt für Gesund-
heit, Schweiz) stellte die spezifischen nationalen 
Vorgaben in der Schweiz vor, wobei er insbe-
sondere die widersprüchliche Situation im Um-
gang mit Nanomaterialien herausarbeitete: Nach 
Einschätzung der OECD sei die Anwendung 
bestehender Testmethoden zur Risikoabschät-
zung von Nanomaterialien prinzipiell geeignet. 
In speziellen Fällen wäre zwar eine Anpassung 
der Richtlinien vorzunehmen, neue Verfahren 
müssten jedoch nicht entwickelt werden. Trotz-
dem wies er auf eine Vielzahl offener Fragen 
hin. Studer präsentierte eine Liste mit insgesamt 
vierzehn konkreten regulatorischen Fragen, u. a. 
zur Messmethodik, physikalisch-chemischen Ei-
genschaften, Langzeiteffekten, Gruppenbildung, 
Wirkmechanismen, Exposition, bis hin zur Risi-
kobewertung und zum Risikomanagement. Die 
Einschätzung der OECD wurde im Anschluss an 
diese Präsentation von den meisten Teilnehmern 
für ihren Kontext als vertrauensbildend und be-
ruhigend bewertet. Insbesondere Hersteller und 
Innovatoren erwarten dadurch eine gewisse Pla-
nungssicherheit für zukünftige Innovationen.
Notes
1) http://en.past-centre.ru/2014/05/conference-so-
cial-sciences-and-medical-innovations/
2) http://tp-medfuture.ru/en
3) http://www.innoclusters.ru/
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